The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
Official Title: An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study
Study ID: NCT01617629
Brief Summary: The purpose of this trial is to assess the safety profile of Cvac for epithelial ovarian cancer patients who were enrolled in the Cvac clinical trial CAN-003 and are no longer eligible for study participation due to disease progression.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Marin Cancer Care, Inc., Greenbrae, California, United States
Scripps Cancer Center, La Jolla, California, United States
Collaborative Research Group, Boca Raton, Florida, United States
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
University of Washington Medical Center, Seattle, Washington, United States
Greenslopes Private Hospital, Greenslopes, Queensland, Australia
Name: Heidy Gray, MD
Affiliation: University of Washington
Role: PRINCIPAL_INVESTIGATOR
Name: James Mason, MD
Affiliation: Scripps Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Name: Peter Eisenberg, MD
Affiliation: Marin Cancer Care
Role: PRINCIPAL_INVESTIGATOR
Name: Giuseppe Del Priore, MD
Affiliation: Indiana University School of Medicine
Role: PRINCIPAL_INVESTIGATOR
Name: Fernando Recio, MD
Affiliation: Collaborative Research Group
Role: PRINCIPAL_INVESTIGATOR
Name: Jeffery Goh, MBBS, FRACP
Affiliation: Greenslopes Private Hospital
Role: PRINCIPAL_INVESTIGATOR